6STRUMBERG D,VOLIOTIS D,MOELLER JG,et al.Results of phase Ⅰ pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors[J].Int J Clin Pharmacol Ther,2002,40(12):580-581.
7LATHIA C,LETTIERI J,CIHON F,et al.Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics[J].Cancer Chemother Pharmacol,2006,57(5):685-692.
8KUPSCH P,HENNING BF,PASSARGE K,et al.Results of a phase Ⅰ trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors,including colorectal cancer[J].Clin Colorectal Cancer,2005,5(3):188-196.
9RICHLY H,HENNING BF,KUPSCH P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43-9006)in combination with doxorubicin in patients with refractory solid tumors[J].Ann Oncol,2006,17(5):866-873.
10RICHLY H,KUPSCH P,PASSAGE K,et al.A phase Ⅰ clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI)BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors[J].Int J Clin Pharmacol Ther,2003,41 (12):620-621.
